Observational research on NCDs in HIV-positive populations: Conceptual and methodological considerations

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue SUPPL.1, 2014, Pages

  Petersen, Maya ^a   Yiannoutsos, Constantin T ^b   Justice, Amy ^c   Egger, Matthias ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

casual inference; cohorts; HIV AIDS; loss to follow up; resource limited settings; Sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ARTICLE; CLINICAL DECISION MAKING; COMORBIDITY; CONFOUNDING VARIABLE; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFORMATION PROCESSING; MATHEMATICAL MODEL; MEDICAL ETHICS; NON COMMUNICABLE DISEASE; OBSERVATIONAL METHOD; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; BIOMEDICAL RESEARCH; COMORBIDITY; DELIVERY OF HEALTH CARE, INTEGRATED; DEVELOPING COUNTRIES; DIAGNOSTIC TESTS, ROUTINE; HIV INFECTIONS; HUMANS; PREVALENCE; PREVENTIVE HEALTH SERVICES; RISK FACTORS;

EID: 84906063795     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000253     Document Type: Article

References (97)

1. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of prospective cohort studies. Nat Rev Genet. 2006;7:812-820.
2. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404-410.
3. Tesoriero JM, Gieryic SM, Carrascal A, et al. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824-835.
4. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-35.
5. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(suppl 3):S375-S382.
6. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525-1533.
7. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39:633-645.
8. Borges ÁH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014;9:34-40.
9. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012;60(suppl 1):S1-S18.
10. Adebamowo CA, Casper C, Bhatia K, et al. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low-and middle-income countries in Africa. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S17-S26.
11. Bloomfield GS, Khazanie P, Morris A, et al. HIV and noncommunicable cardiovascular and pulmonary diseases in low-and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S40-S53.
12. Ebrahim O, Mazanderani AH. Recent developments in HIV treatment and their dissemination in poor countries. Infect Dis Rep. 2013;5(suppl 1):e2.
13. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S112-S117.
14. Berg CJ, Michelson SE, Safren SA. Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin North Am. 2007;21:181-200.
15. Ali MK, Magee MJ, Dave JA, et al. HIV and metabolic, body, and bone disorders: what we know from low-and middle-income countries. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S27-S39.
16. Chibanda D, Benjamin L, Weiss HA, et al. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low-and middle-income countries. J Acquir Immune Defic Syndr. 2014;67(suppl 1): S54-S67.
17. Kalyesubula R, Wearne N, Semitala FC, et al. HIV-associated renal and genitourinary comorbidities in Africa. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S68-S78.
18. Kelly P, Saloojee H, Chen JY, et al. Noncommunicable diseases in HIV infection in low-and middle-income countries: gastrointestinal, hepatic, and nutritional aspects. J Acquir Immune Defic Syndr. 2014;67(suppl 1): S79-S86.
19. Ebrahim S, Pearce N, Smeeth L, et al. Tackling non-communicable diseases in low-and middle-income countries: is the evidence from high-income countries all we need? PLoS Med. 2013;10:e1001377.
20. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24:1455-1481.
21. Rosenblum M, Van der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika. 2011;98:845-860.
22. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health. 2000;21:121-145.
23. Egger M, Ekouevi DK, Williams C, et al. Cohort profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2012;41:1256-1264.
24. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-457.
25. Davies MA. Prognosis of children with HIV-1 infection starting antire-troviral therapy in Southern Africa: a collaborative analysis of treatment programs. Pediatr Infect Dis J. 2014;33:608-616.
26. McGowan CC, Cahn P, Gotuzzo E, et al. Cohort Profile: Caribbean, Central and south America network for HIV research (CCASAnet) collaboration within the international epidemiologic databases to evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007;36:969-976.
27. Wright S, Boyd MA, Yunihastuti E, et al. Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS One. 2013;8:e64902.
28. Rabkin M, El-Sadr W. Saving mothers, saving families: the MTCT-plus initiative. Perspectives and Practice in Antiretroviral Treatment. Geneva, Switzerland: WHO; 2003.
29. Rabkin M, Kruk ME, El-Sadr WM. HIV, aging and continuity care: strengthening health systems to support services for noncommunicable diseases in low-income countries. AIDS. 2012;26(suppl 1):S77-S83.
30. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
31. Ford N, Calmy A, Mills EJ. The first decade of antiretroviral therapy in Africa. Globalization and Health. 2011;7:33.
32. Dillon D, Gurdasani D, Riha J, et al. Association of HIV and ART with cardiometabolic risk factors in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:1754-1771.
33. Short Fabic M, Choi Y, Bird S. A systematic review of demographic and health surveys: data availability and utilization for research. Bull World Health Organ. 2012;90:604-612.
34. Kahn K, Collinson MA, Gómez-Olivé FX, et al. Profile: Agincourt health and socio-demographic surveillance system. Int J Epidemiol. 2012;41: 988-1001.
35. Odhiambo FO, Laserson KF, Sewe M, et al. Profile: the KEMRI/CDC health and demographic surveillance system-Western Kenya. Int J Epidemiol. 2012;41:977-987.
36. Crampin AC, Dube A, Mboma S, et al. Profile: the Karonga health and demographic surveillance system. Int J Epidemiol. 2012;41:676-685.
37. Noncommunicable Diseases and Mental Health Cluster (2005) WHO STEPS Surveillance Manual: The WHO STEPwise Approach to Chronic Disease Risk Factor Surveillance. Geneva, Switzerland: World Health Organization; 2005.
38. Msyamboza KP, Ngwira B, Dzowela T, et al. The burden of selected chronic non-communicable diseases and their risk factors in Malawi: nationwide STEPS survey. PLoS One. 2011;6:e20316.
39. Bärnighausen T, Welz T, Hosegood V, et al. Hiding in the shadows of the HIV epidemic: obesity and hypertension in a rural population with very high HIV prevalence in South Africa. J Hum Hypertens. 2008;22:236-239.
40. Malaza A, Mossong J, Bärnighausen T, et al. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One. 2012;7:e47761.
41. Asiki G, Murphy G, Nakiyingi-Miiro J, et al. The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int J Epidemiol. 2013;42:129-141.
42. National Statistical Office (NSO) and ICF Macro. Malawi. Demographic and Health Survey 2010. Zomba, Malawi: NSO and ICF Macro; 2011.
43. Chamie G, Kwarisiima D, Clark TD, et al. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012;7:e43400.
44. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt). 2008;17:47-55.
45. Miranda JJ, Gilman RH, Smeeth L. Differences in cardiovascular risk factors in rural, urban and rural-to-urban migrants in Peru. Heart. 2011; 97:787-796.
46. Danaei G, Singh GM, Paciorek CJ, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation. 2013;127:1493-1502, 1502e1491-1498.
47. Hoover D, Munoz A, Carey V, et al. The unseen sample in cohort studies: estimation of its size and effect. Stat Med. 1991;10:1993-2003.
48. Hyle EP, Naidoo K, Su AE, et al. HIV, tuberculosis and noncommuni-cable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care? J Acquir Immune Defic Syndr. 2014; 67(suppl 1):S87-S95.
49. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-16.
50. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8: e1001056.
51. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
52. Tassie JM, Baijal P, Vitoria MA, et al. Trends in retention on antiretro-viral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr. 2010;54:437-441.
53. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790.
54. Egger M, Spycher BD, Sidle J, et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med. 2011;8:e1000390.
55. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300:506-507.
56. Geng EH, Glidden DV, Bangsberg DR, et al. A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol. 2012;175:1080-1087.
57. Schoni-Affolter F, Keiser O, Mwango A, et al. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PLoS One. 2011;6:e27919.
58. Van Cutsem G, Ford N, Hildebrand K, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One. 2011;6:e14684.
59. Shepherd BE, Blevins M, Vaz LM, et al. Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. Am J Epidemiol. 2013; 178:819-828.
60. Grimsrud AT, Cornell M, Egger M, et al. Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. J Clin Epidemiol. 2013;66:1006-1013.
61. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
62. Yiannoutsos CT, An MW, Frangakis CE, et al. Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One. 2008;3:e3843.
63. Towards Universal Access. Scaling up priority HIV/AIDS interventions in the health sector. 2009 progress reportA1-World Health Organization. 2009. Available at: http://www.who.int/hiv/pub/2009progressreport/en/index.html. Accessed June 29, 2014.
64. Schomaker M, Gsponer T, Estill J, et al. Non-ignorable loss to follow-up: correcting mortality estimates based on additional outcome ascertainment. Stat Med. 2014;33:129-142.
65. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr. 2007;44:179-187.
66. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
67. Papas RK, Sidle JE, Gakinya BN, et al. Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. Addiction. 2011; 106:2156-2166.
68. Wynder EL. Investigator bias and interviewer bias: the problem of reporting systematic error in epidemiology. J Clin Epidemiol. 1994;47:825-827.
69. Aradottir S, Asanovska G, Gjerss S, et al. PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol. 2006;41:431-437.
70. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a'virtual" cohort using the National VA Health Information System. Med Care. 2006;44:S25-S30.
71. Justice AC, Erdos J, Brandt C, et al. The Veterans Affairs Healthcare System: a unique laboratory for observational and interventional research. Med Care. 2006;44:S7-S12.
72. Geneau R, Hallen G Toward a systemic research agenda for addressing the joint epidemics of HIV/AIDS and noncommunicable diseases. AIDS. 2012;26:S7-S10.
73. Bembom O, Petersen ML, Rhee SY, et al. Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infection. Stat Med. 2009;28:152-172.
74. van der Laan M, Rose S. Targeted Learning: Causal Inference for Observational and Experimental Data. Berlin Heidelberg, New York: Springer; 2011.
75. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
76. Tsai AC, Weiser SD, Petersen ML, et al. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry. 2010;67(12):1282-1290.
77. Petersen ML, Wang Y, van der Laan MJ, et al. Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(suppl 1):S96-S103.
78. Petersen ML, Schwab J, Gruber S, et al. Targeted maximum likelihood estimation for dynamic and static longitudinal marginal structural working models. J Causal Inference. 2014;[ePub ahead of print, June 18, 2014].
79. Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10:e1001381.
80. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd ed. New York, NY: Springer-Verlag; 2009.
81. van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007;6:Article25.
82. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62:149-163.
83. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27:563-572.
84. Greving JP, Visseren FL, de Wit GA, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.
85. van der Laan M, Dudoit S, Keles S. Asymptotic optimality of likelihood-based cross-validation. Stat Appl Genet Mol Biol. 2004;3:Article4.
86. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515-524.
87. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150:795-802.
88. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifica-tion and beyond. Stat Med. 2008;27:157-172
89. HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med. 2012;9:e1001259.
90. Lansang MA, Dennis R. Building capacity in health research in the developing world. Bull World Health Organ. 2004;82:764-770.
91. Breman JG, Bridbord K, Kupfer LE, et al. Global health: the Fogarty International Center, National Institutes of Health: vision and mission, programs, and accomplishments. Infect Disease Clinics North America. 2011;25:511.
92. Heimburger DC, Carothers CL, Gardner P, et al. Nurturing the global workforce in clinical research: the National Institutes of Health Fogarty International Clinical Scholars and Fellows Program. Am J Trop Med Hyg. 2011;85:971-8.
93. Maher D, Biraro S, Hosegood V, et al. Translating global health research aims into action: the example of the ALPHA network. Trop Med Int Health. 2010;15:321-328.
94. Einterz RM, Kimaiyo S, Mengech HN, et al. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med. 2007;82:812-818.
95. Palen J, El-Sadr W, Phoya A, et al. PEPFAR, health system strengthening, and promoting sustainability and country ownership. J Acquir Immune Defic Syndr. 2012;60(suppl 3):S113-S119.
96. Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346:e5595.
97. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.